Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

BBIBP-CorV

Antineutrophil cytoplasmic antibody-associated vasculitis

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Javadian P, et al. Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis following COVID-19 BBIBP-CorV vaccine: A case report. Clinical Infection in Practice 21: Jan 2024. Available from: URL: https://dx.doi.org/10.1016/j.clinpr.2023.100337 Javadian P, et al. Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis following COVID-19 BBIBP-CorV vaccine: A case report. Clinical Infection in Practice 21: Jan 2024. Available from: URL: https://dx.doi.org/10.1016/j.clinpr.2023.100337
Metadaten
Titel
BBIBP-CorV
Antineutrophil cytoplasmic antibody-associated vasculitis
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52563-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Liraglutide

Case report

Apalutamide

Case report

Nivolumab